Novartis is partnering with the International Committee of the Red Cross (ICRC) to improve care and treatment for Syrian refugees in Lebanon suffering from chronic diseases.
The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up of refugees and Lebanese suffering from chronic diseases.
Novartis will provide medicines for high blood pressure and diabetes, diseases that together account for more than 50% of deaths in Lebanon every year. The medicines are being supplied through Novartis Access, a program that focuses on affordability and availability of on- and off-patent medicines addressing key noncommunicable diseases.
The portfolio of medicines is offered to governments and public-sector healthcare providers in lower and lower-middle-income countries at a price of USD 1 per treatment per month.